文献速递心律失常

阿哌沙班剂量与房颤合并重度慢性肾脏病患者的安全性和有效性结局的关联

Associations of Apixaban Dose With Safety and Effectiveness Outcomes in Patients With Atrial Fibrillation and Severe Chronic Kidney Disease.
PubMed 文献 · Circulation · 2023-09-08

本研究利用Optum Labs数据仓库中2013至2021年启动阿哌沙班治疗的房颤合并慢性肾脏病4/5期患者,比较5 mg与2.5 mg剂量的出血和卒中/体循环栓塞风险。结果显示5 mg组出血风险更高,而卒中/体循环栓塞和死亡风险无差异,支持欧洲药品管理局基于肾功能的剂量推荐。

要点

  • 房颤合并CKD 4/5期患者中,5 mg阿哌沙班较2.5 mg出血风险更高。
  • 两种剂量在卒中/体循环栓塞和死亡风险上无显著差异。
  • 结果支持欧洲药品管理局基于肾功能的剂量推荐。

核心结论

  • 与2.5 mg相比,5 mg阿哌沙班与房颤合并重度慢性肾脏病患者更高的出血风险相关,而卒中/体循环栓塞或死亡风险无差异。

研究设计与样本

  • 利用Optum Labs数据仓库的去标识电子健康记录数据,识别2013至2021年启动阿哌沙班的房颤合并慢性肾脏病4/5期患者。
  • 共纳入4313例阿哌沙班新使用者,其中1705例(40%)接受5 mg,2608例(60%)接受2.5 mg。
  • 采用逆概率治疗加权调整基线特征,Fine-Gray子分布风险模型考虑死亡竞争风险,Cox回归分析死亡风险。

主要发现

  • 5 mg组较2.5 mg组出血发生率更高(每100人年4.9 vs 2.9;发生率差2.0 [95% CI, 0.6-3.4];子分布风险比1.63 [95% CI, 1.04-2.54])。
  • 两组卒中/体循环栓塞风险无差异(每100人年3.3 vs 3.0;发生率差0.2 [95% CI, -1.0 to 1.4];子分布风险比1.01 [95% CI, 0.59-1.73])。
  • 两组死亡风险无差异(每100人年9.9 vs 9.4;发生率差0.5 [95% CI, -1.6 to 2.6];风险比1.03 [95% CI, 0.77-1.38])。

临床怎么用

  • 对于房颤合并慢性肾脏病4/5期患者,选择阿哌沙班剂量时应权衡出血风险,5 mg较2.5 mg出血风险更高。
  • 研究结果支持欧洲药品管理局基于肾功能的阿哌沙班剂量推荐,而非美国食品药品管理局的推荐。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Recommendations for apixaban dosing on the basis of kidney function are inconsistent between the US Food and Drug Administration and European Medicines Agency for patients with atrial fibrillation. Optimal apixaban dosing in chronic kidney disease remains unknown. METHODS: With the use of deidentified electronic health record data from the Optum Labs Data Warehouse, patients with atrial fibrillation and chronic kidney disease stage 4/5 initiating apixaban between 2013 and 2021 were identified. Risks of bleeding and stroke/systemic embolism were compared by apixaban dose (5 versus 2.5 mg), adjusted for baseline characteristics by the inverse probability of treatment weighting. The Fine-Gray subdistribution hazard model was used to account for the competing risk of death. Cox regression was used to examine risk of death by apixaban dose. RESULTS: Among 4313 apixaban new users, 1705 (40%) received 5 mg and 2608 (60%) received 2.5 mg. Patients treated with 5 mg apixaban were younger (mean age, 72 versus 80 years), with greater weight (95 versus 80 kg) and higher serum creatinine (2.7 versus 2.5 mg/dL). Mean estimated glomerular filtration rate was not different between the groups (24 versus 24 mL·min-1·1.73 m-2). In inverse probability of treatment weighting analysis, apixaban 5 mg was associated with a higher risk of bleeding (incidence rate 4.9 versus 2.9 events per 100 person-years; incidence rate difference, 2.0 [95% CI, 0.6-3.4] events per 100 person-years; subdistribution hazard ratio, 1.63 [95% CI, 1.04-2.54]). There was no difference between apixaban 5 mg and 2.5 mg groups in the risk of stroke/systemic embolism (3.3 versus 3.0 events per 100 person-years; incidence rate difference, 0.2 [95% CI, -1.0 to 1.4] events per 100 person-years; subdistribution hazard ratio, 1.01 [95% CI, 0.59-1.73]), or death (9.9 versus 9.4 events per 100 person-years; incidence rate difference, 0.5 [95% CI, -1.6 to 2.6] events per 100 person-years; hazard ratio, 1.03 [95% CI, 0.77-1.38]). CONCLUSIONS: Compared with 2.5 mg, use of 5 mg apixaban was associated with a higher risk of bleeding in patients with atrial fibrillation and severe chronic kidney disease, with no difference in the risk of stroke/systemic embolism or death, supporting the apixaban dosing recommendations on the basis of kidney function by the European Medicines Agency, which differ from those issued by the US Food and Drug Administration.

来源:Circulation,查看原文。版权归原作者所有。

引用

  1. Xu Y, Chang AR, Inker LA, et al. Associations of Apixaban Dose With Safety and Effectiveness Outcomes in Patients With Atrial Fibrillation and Severe Chronic Kidney Disease. Circulation. 2023. PMID: 37681341. doi:10.1161/CIRCULATIONAHA.123.065614

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。